


Recombinant Human IgSF11 ECD-Human Fc

Catalog Number/Size:	P1002-100	100 µg
	P1002-200	200 µg
	P1002-B	Bulk
Source:	Human IgSF11 (Accession# AAH34411.1) extracellular domain (Ser21-Arg237) fused with human IgG1 Fc produced from CHO cells.	
	Human IgSF11 (Ser21-Arg237) Accession# NP AAH34411.1	SGGGG Human IgG1 (Asp104-Lys330)
	N-terminal	C-terminal
Structure:	Disulfide-linked homodimer	
Predicted N-terminal:	Ser 21	
Predicted Molecular Weight:	48.9 kDa (monomer)	
Apparent Molecular Weight on SDS-PAGE:	55.0 kDa, reducing conditions	
Formulation:	0.22 µm filtered protein solution in PBS	
Storage:	-20°C or below	
Estimated Purity:	>95% as determined by SDS-PAGE	
Protein Endotoxin level:	Not measured	
Protein Aggregation:	Insignificant on SDS-PAGE	

DATA



Disclaimer: For research use only. Not for use in humans.

Recombinant Human IgSF11 ECD-Human Fc

Application:	Biochemical analysis
Product Description:	IgSF11 is a member of the immunoglobulin superfamily. It has a 23-residue signal peptide, 3 potential extracellular N-linked glycosylation sites, an extracellular V-type Ig-like domain, an extracellular C2-type Ig-like domain, and a 170-residue cytoplasmic tail with a C-terminal PDZ-interacting motif (1). IgSF11 functions as an adhesion molecule with homophilic molecular interaction (2). It is a 52-kD glycoprotein that is expressed highest in testis, and lower in brain, kidney, and adrenal gland. Within brain, expression in the corpus callosum was comparable to that in testis (1). It is suggested to be a diagnostic and/or clinical target for gastric cancer (3).
Other Names:	VSIG3, BT-IgSF, CT119
References:	<ol style="list-style-type: none">1. Suzu, S. <i>et al.</i> (2002) <i>Biochem. Biophys. Res. Commun.</i> 265:1215.2. Harada, H. <i>et al.</i> (2005) <i>J. Cell. Physiol.</i> 204:919.3. Katoh, M. and Katoh, M. (2003) <i>Int. J. Oncol.</i> 23:525.

Disclaimer: For research use only. Not for use in humans.